Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
benzodiazepine
controlled substance sedative-hypnotic drug |
| gptkbp:ATCCode |
N05CA06
|
| gptkbp:brand |
gptkb:Seconal
gptkb:Seconal_Sodium |
| gptkbp:CASNumber |
309-43-3
|
| gptkbp:chemicalFormula |
C12H17N2NaO3
|
| gptkbp:color |
white
|
| gptkbp:contraindication |
porphyria
severe respiratory insufficiency hypersensitivity to barbiturates |
| gptkbp:discoveredBy |
gptkb:Donalee_L._Tabern
gptkb:Ernest_H._Volwiler |
| gptkbp:discoveredIn |
1928
|
| gptkbp:eliminationHalfLife |
15-40 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:form |
crystalline powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
secobarbital sodium
|
| gptkbp:legalStatus |
gptkb:Schedule_II_(US)
Prescription only |
| gptkbp:listedOn |
World Health Organization Model List of Essential Medicines (historically)
|
| gptkbp:marketedAs |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:mechanismOfAction |
GABA-A receptor positive allosteric modulator
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
272.27 g/mol
|
| gptkbp:overdoseSymptoms |
death
coma |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
dizziness
drowsiness respiratory depression dependence |
| gptkbp:solubility |
water-soluble
|
| gptkbp:synonym |
quinalbarbitone sodium
sodium secobarbital |
| gptkbp:UNII |
H3G3K65W8M
|
| gptkbp:usedFor |
insomnia
seizure control preoperative sedation |
| gptkbp:usedIn |
physician-assisted suicide (in some jurisdictions)
|
| gptkbp:bfsParent |
gptkb:Secobarbital
|
| gptkbp:bfsLayer |
7
|